Tau Toxicity in the Synapses

Tau toxicity has been implicated in the emergence of synaptic dysfunction in Alzheimer's disease. Here is the latest research on Tau Toxicity in the Synapses.

February 23, 2021

Role of Hypoxia Inducible Factor-1α in Alzheimer's Disease.

Journal of Alzheimer's Disease : JAD
Yang-Yang WangZhi-You Cai
February 23, 2021
Open Access

Flavonoid-Based Nanomedicines in Alzheimer's Disease Therapeutics: Promises Made, a Long Way To Go.

ACS Pharmacology & Translational Science
Pragya Prasanna, Arun Upadhyay
February 20, 2021

CREB: A Multifaceted Target for Alzheimer's Disease.

Current Alzheimer Research
Vivek Kumar Sharma, Thakur Gurjeet Singh
February 16, 2021

Cellular and molecular mechanisms of Dementia: Decoding the causal link of Diabetes Mellitus in Alzheimer's disease.

CNS & Neurological Disorders Drug Targets
Mahmood RasoolPeter Natesan Pushparaj
February 14, 2021
Open Access

Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation.

Cell Communication and Signaling : CCS
Shweta Kishor SonawaneSubashchandrabose Chinnathambi
February 12, 2021
Open Access

Defined Tau Phosphospecies Differentially Inhibit Fast Axonal Transport Through Activation of Two Independent Signaling Pathways.

Frontiers in Molecular Neuroscience
Sarah L MorrisScott T Brady
February 11, 2021
Open Access

Tau Protein Preferentially Associates With Synaptic Mitochondria in a Mouse Model of Tauopathy

Andrew J TreaseKelly Stauch
February 10, 2021
Open Access

Cholesterol Alters Mitophagy By Impairing Optineurin Recruitment And Lysosomal Clearance In Alzheimer’s Disease

Vicente Roca-AgujetasAnna Colell
February 10, 2021
Open Access

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.

Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Nicholas J IzzoSusan M Catalano
February 9, 2021
Open Access

Does Impairment of Adult Neurogenesis Contribute to Pathophysiology of Alzheimer's Disease? A Still Open Question.

Frontiers in Molecular Neuroscience
D. D. Li PumaC. Grassi
February 4, 2021
Open Access

Porphyromonas gingivalis is a Strong Risk Factor for Alzheimer's Disease.

JAD Reports
Shalini KanagasingamSim K Singhrao
February 2, 2021
Open Access

The Synaptic Dysregulation in Adolescent Rats Exposed to Maternal Immune Activation.

Frontiers in Molecular Neuroscience
Magdalena CieślikAgata Adamczyk
February 2, 2021

Interaction of NF-κB and Wnt/β-catenin Signaling Pathways in Alzheimer's Disease and Potential Active Drug Treatments.

Neurochemical Research
Xiao LiuXiaoying Wang
February 1, 2021
Open Access

TMEM97 increases in synapses and is a potential synaptic Aβ binding partner in human Alzheimer's disease

BioRxiv : the Preprint Server for Biology
M. Colom-CadenaTara L Spires-Jones
January 30, 2021

[Network pharmacology-based study of the therapeutic mechanism of resveratrol for Alzheimer's disease].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University
Yingyan FangPeng Zeng
January 29, 2021

Review of Evidence and Perspectives of Flavonoids on Metabolic Syndrome and Neurodegenerative Disease.

Protein and Peptide Letters
Aline M Hilzendeger Zilli, Eduardo M Zilli

Sign up to follow this feed and discover related papers.

Related Feeds

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Animal Models

Alzheimer's disease is a neurodegenerative disease which can be studied using various experimental systems. This feed focuses on animal models used for Alzheimer's disease research.

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Endosomes

Dysfunctional endosomal trafficking may be associated with Alzheimer’s disease (AD) pathology. Targeting the endosome may advance treatment options for AD. Here is the latest research on endosomes and AD.

Alzheimer's Disease: Genetics

Alzheimer's disease is a neurodegenerative disease. Discover genetic and epigenetic aspects of Alzheimer’s disease, including genetic markers and genomic structural variations with this feed.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Alzheimer's Disease: Microglia

Microglia are a type of glial cell found throughout the brain and spinal cord. Microglia have been found to be associated with Alzheimer's disease development and progression. Here are the latest discoveries pertaining to Alzheimer's disease and microglia.

© 2021 Meta ULC. All rights reserved